Vasomedical Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc.

VASO 0.160

+6.7%

12:31 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Craig Slotoroff who started this subject	6/26/2001 11:12:44 AM
From: 613	Read Replies (1) of 1605

Vasomedical: Study Shows EECP Therapy Reduces Angina June 25, 2001 Dow Jones News Service (Copyright (c) 2001, Dow Jones & Company, Inc.) WESTBURY, N.Y. -(Dow Jones)- Vasomedical Inc. (VASO) released a study showing EECP enhanced external counterpulsation therapy is as effective in reducing angina in patients with diabetes as it is in patients without diabetes. In a press release Monday, the company said EECP is a noninvasive, outpatient therapy for the treatment of diseases of the cardiovascular system. There are about 1 million people in the United States with Type 1 diabetes and 15 million with Type 2 diabetes. Diabetic patients have greater risks for cardiovascular disease than the general population.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next